When a figure from his past turns up to a family funeral, a college professor faces an agonising dilemma that makes him question his own morality and whether he can change Paul Schrader is back with ...
The FDA has approved the first RAS-targeted therapy for metastatic pancreatic cancer, offering a new treatment option for patients with previously treated disease. Daraxonrasib (Rasonque, Revolution ...
As the siege enters its second week, 15 Palestinians, including two children, remain besieged inside three homes in the Ras al-Ain area of Qusra, south of Nablus. Surrounded by armed Israeli settlers ...
The RAS family commonly drives the growth and survival of human cancers. Mutations in KRAS, NRAS, and HRAS occur in approximately 20% of all human cancers, including solid tumors, such as pancreatic, ...
Unmanned Surface Vessel Division 12 (Sea Hunter) and 13 (Sea Hunter) conduct unit level training underway in San Diego Bay, California, May 1, 2025. US Navy photo The Navy’s portfolio acquisition ...
Delta is cutting up the front of the plane by introducing new classes, including "basic business." The cheaper Delta One fares won't come with airport lounge access or seat assignments. Rival United ...
Pancreatic cancer remains one of the most difficult malignancies to treat. The unmet need is clear, but so is the risk of drug development in a disease where progress has often been limited. For Alan ...
Authorities confirm deaths, say 66 injured Authorities say a 'technical accident' caused explosion Blast occurred during restart at Barzan gas supply facility DOHA, June 22 (Reuters) - Thirteen people ...
b RAS G12, G13 or Q61 mut or no RAS mut identified. This is an ASCO Meeting Abstract from the 2026 ASCO Annual Meeting II. This abstract does not include a full text component.
This year’s meeting of the American Society of Clinical Oncology is abuzz with talk of RAS inhibitors, largely driven by Revolution Medicines’ barnburner pancreatic cancer data drop earlier this year.
Current therapies offer limited benefit for patients with previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Aberrant activation of the RAS pathway is the key driver of PDAC, with ...
RAS mutations are among the most common drivers in cancer, particularly in pancreatic, colorectal, and lung tumors. Despite that, directly targeting RAS proteins proved extremely difficult for years, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results